Please use this identifier to cite or link to this item: https://zone.biblio.laurentian.ca/handle/10219/4102
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCooke, Emily-
dc.date.accessioned2023-12-15T22:59:21Z-
dc.date.available2023-12-15T22:59:21Z-
dc.date.issued2023-10-30-
dc.identifier.urihttps://zone.biblio.laurentian.ca/handle/10219/4102-
dc.descriptionMajor Research Paper in Science Communication.en_US
dc.descriptionSupervised by Dr. Chantal Barriault and Dr. Jeff Gagnon.en_US
dc.description.abstractThe growing prevalence of type 2 diabetes mellitus (T2DM) has been accompanied by the development of new medications for treating the condition. One such medication is semaglutide, which has been extensively discussed in the media under its brand name Ozempic due to its potential for causing weight loss. Amidst the growing discourse surrounding Ozempic, alongside evidence that patient information sources can be inaccessible or unreliable, the research question addressed here is: how is the framing of information on Ozempic, from passive and active information sources, impacting how patients with T2DM in Canada come to understand and make decisions regarding their health? The approach to answering this question involved collecting artifacts from passive and active information sources, before performing first a content then closer rhetorical analysis to discover which frames, or terministic screens, were employed. It was observed through this analysis that passive sources like news and social media often exclude much of the science behind Ozempic to focus on the weight loss discourse. These sources also sometimes provide inaccurate scientific information, which can be misleading to patients. The active sources like websites and pharmacy handouts, meanwhile, cover more, though not all, of the science behind Ozempic, but their complexity and structure can make the information more difficult to comprehend. Overall, it is clear that no single source provides comprehensive coverage of Ozempic to allow T2DM patients to make informed decisions, and even spread across multiple source types, gaps remain that need to be addressed.en_US
dc.language.isoenen_US
dc.subjectOzempicen_US
dc.subjectHealth informationen_US
dc.subjectType 2 diabetes patientsen_US
dc.subjectMediaen_US
dc.subjectTerministic screensen_US
dc.titleDigesting Ozempic: How information sources on the type 2 diabetes drug Ozempic can affect patient understanding and decision makingen_US
dc.typeOtheren_US
dc.description.degreeMaster of Science Communicationen_US
dc.publisher.grantorLaurentian University of Sudburyen_US
Appears in Collections:Science Communication - Major Research Papers

Files in This Item:
File Description SizeFormat 
EC_Major Research Paper (FINAL).pdfMSCom Major Research Paper4 MBAdobe PDFThumbnail
View/Open


Items in LU|ZONE|UL are protected by copyright, with all rights reserved, unless otherwise indicated.